| 0.0992 -0.007 (-6.15%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.37 | 1-year : | 0.54 |
| Resists | First : | 0.32 | Second : | 0.46 |
| Pivot price | 0.21  |
|||
| Supports | First : | 0.08 | Second : | 0.07 |
| MAs | MA(5) : | 0.1 |
MA(20) : | 0.25 |
| MA(100) : | 0.37 |
MA(250) : | 3.12 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.5 |
D(3) : | 2.5 |
| RSI | RSI(14): 27.2 |
|||
| 52-week | High : | 15.8 | Low : | 0.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ASBP ] has closed above bottom band by 25.4%. Bollinger Bands are 105.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.11 - 0.11 | 0.11 - 0.11 |
| Low: | 0.09 - 0.09 | 0.09 - 0.09 |
| Close: | 0.1 - 0.1 | 0.1 - 0.1 |
Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.
Tue, 18 Nov 2025
Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Mon, 17 Nov 2025
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Fri, 14 Nov 2025
Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Fri, 14 Nov 2025
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 45 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 918 (K) |
| Shares Short P.Month | 809 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -64.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | -0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|